Limits...
Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13.

Li P, Deng J, Wei X, Jayasuriya CT, Zhou J, Chen Q, Zhang J, Wei L, Wei F - Mol Med Rep (2016)

Bottom Line: Binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its receptor C-X-C chemokine receptor type 4 (CXCR4) results in receptor activation and the subsequent release of matrix metalloproteinases (MMPs) that contribute to osteoarthritis (OA) cartilage degradation.By contrast, such changes did not occur to an appreciable degree in cells that were pretreated with AMD3100.The results of the present study demonstrate that even under hypoxic conditions, where CXCR4 expression is significantly elevated in chondrocytes, AMD3100 effectively blocks this receptor and protects chondrocytes from OA‑induced catabolism, suggesting that the successful inhibition of CXCR4 may be an effective approach for OA treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, Shanxi 030001, P.R. China.

ABSTRACT
Binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its receptor C-X-C chemokine receptor type 4 (CXCR4) results in receptor activation and the subsequent release of matrix metalloproteinases (MMPs) that contribute to osteoarthritis (OA) cartilage degradation. As hypoxia is a defining feature of the chondrocyte microenvironment, the present study investigated the possible mechanism through which SDF‑1 induces cartilage degradation under hypoxic conditions. To do this, OA chondrocyte cultures and patient tissue explants pretreated with the CXCR4 inhibitor, AMD3100 were incubated with SDF‑1. It was identified that hypoxic conditions significantly elevated the expression of CXCR4 in osteoarthritic chondrocytes relative to normoxic conditions. Furthermore, SDF‑1 elevated MMP‑13 mRNA levels and proteinase activity. It also elevated the mRNA and protein levels of runt‑related transcription factor 2, and induced the release of glycosaminoglycans and the inflammatory cytokine, interleukin‑1β. By contrast, such changes did not occur to an appreciable degree in cells that were pretreated with AMD3100. The results of the present study demonstrate that even under hypoxic conditions, where CXCR4 expression is significantly elevated in chondrocytes, AMD3100 effectively blocks this receptor and protects chondrocytes from OA‑induced catabolism, suggesting that the successful inhibition of CXCR4 may be an effective approach for OA treatment.

No MeSH data available.


Related in: MedlinePlus

SDF-1-induced GAG release decreased in response to AMD3100 pretreatment in osteoarthritis cartilage explants. Free GAG content was significantly higher in media collected from explants treated with SDF-1 vs. explants without SDF-1 treatment or explants pre-treated with AMD3100 prior to SDF-1 incubation. This effect of SDF-1 was significantly reduced in the explants that were pretreated with AMD3100. Data are presented as means + standard deviation. SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; GAG, glycosaminoglycan.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940083&req=5

f5-mmr-14-02-1475: SDF-1-induced GAG release decreased in response to AMD3100 pretreatment in osteoarthritis cartilage explants. Free GAG content was significantly higher in media collected from explants treated with SDF-1 vs. explants without SDF-1 treatment or explants pre-treated with AMD3100 prior to SDF-1 incubation. This effect of SDF-1 was significantly reduced in the explants that were pretreated with AMD3100. Data are presented as means + standard deviation. SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; GAG, glycosaminoglycan.

Mentions: GAG is an important structural component of proteoglycans and its release is a marker of proteoglycan catabolism (27). To further examine whether SDF-1 causes cartilage matrix degradation, the concentration of GAG in the conditioned media of explants treated with SDF-1 was determined by spectrophotometry using a DMMB assay, in which bovine chondroitin sulfate served as a standard. The level of GAG was significantly higher in media collected from explants treated with SDF-1 vs. explants cultured in the absence of SDF-1 (P=0.001) or explants pretreated with AMD3100 prior to SDF-1 incubation (P=0.004; Fig. 5).


Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13.

Li P, Deng J, Wei X, Jayasuriya CT, Zhou J, Chen Q, Zhang J, Wei L, Wei F - Mol Med Rep (2016)

SDF-1-induced GAG release decreased in response to AMD3100 pretreatment in osteoarthritis cartilage explants. Free GAG content was significantly higher in media collected from explants treated with SDF-1 vs. explants without SDF-1 treatment or explants pre-treated with AMD3100 prior to SDF-1 incubation. This effect of SDF-1 was significantly reduced in the explants that were pretreated with AMD3100. Data are presented as means + standard deviation. SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; GAG, glycosaminoglycan.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940083&req=5

f5-mmr-14-02-1475: SDF-1-induced GAG release decreased in response to AMD3100 pretreatment in osteoarthritis cartilage explants. Free GAG content was significantly higher in media collected from explants treated with SDF-1 vs. explants without SDF-1 treatment or explants pre-treated with AMD3100 prior to SDF-1 incubation. This effect of SDF-1 was significantly reduced in the explants that were pretreated with AMD3100. Data are presented as means + standard deviation. SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; GAG, glycosaminoglycan.
Mentions: GAG is an important structural component of proteoglycans and its release is a marker of proteoglycan catabolism (27). To further examine whether SDF-1 causes cartilage matrix degradation, the concentration of GAG in the conditioned media of explants treated with SDF-1 was determined by spectrophotometry using a DMMB assay, in which bovine chondroitin sulfate served as a standard. The level of GAG was significantly higher in media collected from explants treated with SDF-1 vs. explants cultured in the absence of SDF-1 (P=0.001) or explants pretreated with AMD3100 prior to SDF-1 incubation (P=0.004; Fig. 5).

Bottom Line: Binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its receptor C-X-C chemokine receptor type 4 (CXCR4) results in receptor activation and the subsequent release of matrix metalloproteinases (MMPs) that contribute to osteoarthritis (OA) cartilage degradation.By contrast, such changes did not occur to an appreciable degree in cells that were pretreated with AMD3100.The results of the present study demonstrate that even under hypoxic conditions, where CXCR4 expression is significantly elevated in chondrocytes, AMD3100 effectively blocks this receptor and protects chondrocytes from OA‑induced catabolism, suggesting that the successful inhibition of CXCR4 may be an effective approach for OA treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, Shanxi 030001, P.R. China.

ABSTRACT
Binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its receptor C-X-C chemokine receptor type 4 (CXCR4) results in receptor activation and the subsequent release of matrix metalloproteinases (MMPs) that contribute to osteoarthritis (OA) cartilage degradation. As hypoxia is a defining feature of the chondrocyte microenvironment, the present study investigated the possible mechanism through which SDF‑1 induces cartilage degradation under hypoxic conditions. To do this, OA chondrocyte cultures and patient tissue explants pretreated with the CXCR4 inhibitor, AMD3100 were incubated with SDF‑1. It was identified that hypoxic conditions significantly elevated the expression of CXCR4 in osteoarthritic chondrocytes relative to normoxic conditions. Furthermore, SDF‑1 elevated MMP‑13 mRNA levels and proteinase activity. It also elevated the mRNA and protein levels of runt‑related transcription factor 2, and induced the release of glycosaminoglycans and the inflammatory cytokine, interleukin‑1β. By contrast, such changes did not occur to an appreciable degree in cells that were pretreated with AMD3100. The results of the present study demonstrate that even under hypoxic conditions, where CXCR4 expression is significantly elevated in chondrocytes, AMD3100 effectively blocks this receptor and protects chondrocytes from OA‑induced catabolism, suggesting that the successful inhibition of CXCR4 may be an effective approach for OA treatment.

No MeSH data available.


Related in: MedlinePlus